AKTX stock news

The company has announced the design of its Phase 3 pediatric trial in HSCT-TMA after an end-of-Phase 2 meeting with the FDA. The post Akari Therapeutics Announces Phase 3 Trial Design appeared first on Investing News Network . Read more
Update on Paroxysmal Nocturnal Hemoglobinuria (PNH) Long Term Safety Study Shows 100% Transfusion Independence Two-part pivotal Phase III study of… Read more
Treatment with nomacopan in six patients in Phase II trial was well tolerated and resulted in rapid onset of clinical improvement in five of six patients– No reported. Read more
The FDA grants orphan drug status to Akari's (AKTX) nomacopan for the treatment of bullous pemphigoid, a severe blistering skin condition. Read more
The FDA assigns an orphan drug status to Akari's (AKTX) nomacopan for the treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy, which is a rare disease. Read more
Shares of Akari Therapeutics PLC rocketed 61% to pace all premarket gainers in very active trading Wednesday, after the biopharmaceutical company said its… Read more
The thinly traded, nano-cap biotech Akari Therapeutics PLC (NASDAQ: AKTX) gap-opened higher Wednesday morning, and shares were advancing strongly on … Read more
Anyone researching Akari Therapeutics, Plc (NASDAQ:AKTX) might want to consider the historical volatility of the share… Read more
Akari (AKTX) presents favorable safety data from part A of an early-stage study on nomacopan for treating moderate to severe atopic keratoconjunctivitis. Shares appreciate. Read more
Shares of Akari Therapeutics PLC (NASDAQ: AKTX ) — a thinly traded nano-cap biotech focusing on therapies for autoimmune and inflammatory diseases — were soaring Wednesday. What Happened Akari announced positive results for Part A of a Phase 1/2 study dubbed TRACKER that evaluated the safety and efficacy of its topical nomacopan in moderate to severe atopic keratoconjunctivitis. The Part A portion of the midstage study evaluated three patients who were administered nomacopan eye drops twice daily in addition to cyclosporin, the standard of care, for up to 56 days. The … Full story available on Benzinga.com Read more

Akari Therapeutics EPS beats by $0.05

12:06pm, Wednesday, 29'th May 2019
Read more
In an experimental back of the eye, autoimmune uveitis (EAU) model to be reported in a poster presentation at ARVO 2019, nomacopan (Coversin) and its long acting variants administered intravitreally, reported: ○ Significant improvement in clinical scoring versus control ○ Co-localization of LTB4 and C5a receptors in retinal inflammatory cells seen for the first time ○ Significant downregulation of pro-inflammatory T-helper 17 cells and the inflammatory cytokine IL-17 ○ Efficacy of LTB4 and C5 inhibition, supporting its potential as a novel, non-steroidal therapy across a range of severe ‘back-of-eye' diseases In a "first in eye" Phase I/II study in atopic keratoconjunctivitis (AKC) initial surface of the eye data from the first two patients, treated topically, nomacopan (Coversin) demonstrated: ○ No serious drug related adverse events and good tolerability ○ Rapid improvement in mean comfort and composite efficacy endpoint scores compared to baseline on cyclosporin ○ In allergic conjunctivitis, an eye surface disease, elevated levels of LTB4 were observed NEW YORK and LONDON, April 26, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ: AKTX ), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, announced encouraging new data in both the surface and the back of the eye. "This positive initial data from our ophthalmology program supports the potential efficacy of LTB4 and C5 inhibition in eye surface and back-of-the-eye diseases. Read more
NEW YORK , April 24, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACB, AKTX, ATOS, BA, and RBZ. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. ACB: Full story available on Benzinga.com Read more

Akari Therapeutics reports Q4 results

08:13pm, Tuesday, 23'rd Apr 2019
Akari Therapeutics (AKTX): Q4 GAAP EPS of $0.00. Cash of $5.4M Press Release Read more

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

Proudly Made At

ROCKIT